Genentech News

Just after I posted about the awesome power of federal courts to enjoin other cases , the Federal Circuit reminds us the power is not absolute.

Silicon Valley's companies aren't the only ones poaching each other's intellectual property.

The biggest concern of the biotechnology industry caused by the impending Supreme Court decision in the AMP v. Myriad Genetics case is the threat to existing patents having claims to isolated human DNA that a negative decision from the Court could raise.

Relypsa, Inc., a biopharmaceutical company advancing lead product candidate, patiromer for the treatment of hyperkalemia, in a pivotal Phase 3 clinical study, announced today the appointment of John Orwin as Chief Executive Officer of Relypsa.

At the meeting, Genentech medicines will be highlighted in more than 275 abstracts, of which approximately one third were chosen for oral presentations.

SOUTH SAN FRANCISCO, Calif. & NORTHBROOK, Ill. -- -- Genentech, a member of the Roche Group and Astellas Pharma US, Inc.

Genentech Inc. won regulatory approval Tuesday to use its cancer drug Tarceva and a companion diagnostic for non-small cell lung cancer patients with a rare gene mutation.

Bristol-Myers Squibb Co. v. Genentech, Inc. et al. 3:13-cv-02045; filed May 3, 2013 in the Northern District of California Declaratory judgment of invalidity, unenforceability, and noninfringement of of U.S. Patent Nos.

What if the government could save hundreds of millions of dollars by listing a cheaper drug, shown to be just as effective as the one which costs the PBS more than any other medicine? You won't find out so long as the company that owns both drugs keeps the bargain-priced cousin shut out.

Genentech Inc.'s cancer-fighting Avastin has been linked to 52 cases of flesh-eating disease over 15 years, prompting updated warnings by health authorities.

GlobalData's clinical trial report, "Retinal Vein Occlusion Global Clinical Trials Review, H1, 2013" provides data on the Retinal Vein Occlusion clinical trial scenario.

For as long as I can remember, it's been fashionable for management consultants to attribute many of the challenges of biopharmaceutical companies to scientists run amuck .

Art Levinson is on the board of NGM Biopharmaceuticals, which has raised about $13.5 million in an equity offering.

GlobalData's clinical trial report, "Vasculitis Global Clinical Trials Review, H1, 2013" provides data on the Vasculitis clinical trial scenario.

The medicine can be used in children two years of age and older with active disease.

Genentech employees alight from one of the company's "gene buses" after arriving at work in South San Francisco.

Press: Dalradian Reports Update From C-Vein Sampling at the Curraghinalt Gold Deposit in Northern Ireland: 0.76 m of 33.6 g/t Gold Becomes 7.21 m of 7.58 g/t Gold Dalradian Resources Inc.

Swiss drugmaker Roche Holding AG said it would dissolve its Applied Science business, leading to 170 job cuts in Germany and the United States as price pressures and funding cuts in life-science research weigh.

We're getting old, and no biotech drug, pharmaceutical or enhancing cosmeceutical is going to change a cruel fact: We've got roughly 70 to 100 years on this planet.